

**18 May 2010**
**June 2010 Pharmaceutical Schedule Dispatch**

This document is provided to pharmacists as an early notification of the changes to be announced in the **June 2010** Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

**New listings**

- Enalapril (Arrow-Enalapril) tab 5 mg (p'code: 2358794), 10 mg (p'code: 2358808) and 20 mg (p'code: 2358816)
- Nandrolone decanoate (Deca-Durabolin Orgaject) inj 50 mg per ml, 1 ml – Retail pharmacy–Specialist – Section 29 (p'code: 2353865)
- Tramadol hydrochloride (Arrow-Tramadol) cap 50 mg (p'code: 2351889)
- Cytarabine (Pfizer) inj 500 mg (p'code: 2359510) and 1 g (p'code: 2359529) – Retail pharmacy–Specialist
- Cytarabine (Pfizer) inj 2 g – PCT only - Specialist (p'code: 2359537)
- Irinotecan (Irinotecan-Rex) inj 20 mg per ml, 2 ml (p'code: 2351005) and inj 20 mg per ml, 5 ml (p'code: 2351013)
- Mitomycin-C (Arrow) inj 5 mg – PCT only – Specialist – Section 29 (p'code: 2358832)

**Changes to restrictions**

- Pancreatic enzyme (Cotazym ECS, Creon 10000, Creon Forte, Panzytrat) cap – removal of Retail pharmacy–Specialist restriction
- Ferrous sulphate (Ferodan) oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) – amended presentation
- Malathion (Derbac-M) liq 0.5% – addition of Original Pack (OP) status
- Combined oral contraceptives – removal of delisted brand names in Special Authority criteria
- Progesterone-only contraceptives – removal of delisted brand names in Special Authority criteria
- Alendronate for osteoporosis – amended Special Authority criteria
- Naltrexone hydrochloride (ReVia) tab 50 mg – amended Special Authority criteria
- Cytarabine (Pfizer, Mayne) inj 500 mg, 1 g and 2 g – amended presentation
- Cytarabine (Baxter) inj 1 mg for ECP – amended of unit of measure

**Decreased subsidy**

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Docusate sodium	Tab 50 mg and 120 mg	Laxofast 50 and 120	Coloxyl
Risperidone	Tab 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg	Ridal*, Risperdal, Apo-Risperidone and Dr Reddy's Risperidone	
Cytarabine	Inj 100 mg	Pfizer, Mayne	
Vincristine sulphate	Inj 1 mg per ml, 2 ml Inj 1 mg for ECP	Hospira Baxter	

\* The Ridal brand is the only brand with a subsidy and price change via reference pricing from 1 June 2010.

**Increased subsidy**

Chemical	Presentation	Fully subsidised brands
Cytarabine	Inj 1 mg for ECP	Baxter
Vincristine sulphate	Inj 1 mg per ml, 1 ml	Hospira

**NB.** For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: [www.pharmac.govt.nz/healthpros/Schedule](http://www.pharmac.govt.nz/healthpros/Schedule).

**Fixing the Niggles**

PHARMAC has an ongoing strategy of, where possible, amending the Pharmaceutical Schedule to reduce unnecessary administrative burden for pharmacists. One recent example of this includes addition of OP status to malathion liquid (this month). If you notice any other area that you feel may be improved upon, please do not hesitate to contact us on 0800 66 00 50.